Condoms labeling
This article was originally published in The Tan Sheet
Executive Summary
"It is critically important that FDA inform consumers that condoms do not provide effective protection against infection that can cause cervical cancer as required by law," Rep. Mark Souder (R-Ind.) maintains in a letter inviting FDA, NCI, CDC and Centers for Medicare & Medicaid Services to a Jan. 28 House Government Reform/Human Resources Subcommittee hearing. Indiana Republican points to a 2001 report by the National Institute of Allergy & Infectious Diseases showing "evidence is currently insufficient" to assess condom use for prevention of HPV, among other STDs (1"The Tan Sheet" July 23, 2001, p. 13). Souder's letter notes that Public Law 106-554, enacted in 2000, mandates that FDA "reexamine existing condom labels...to determine whether the labels are medically accurate regarding the overall effectiveness or lack of effectiveness in preventing sexually transmitted diseases, including HPV." Hearing is slated for 10 a.m. in Room 2154, Rayburn House Office Building...
You may also be interested in...
Condom HPV labeling
Reps. Tom Davis (R-Va.) and Mark Souder (R-Ind.) are pressing FDA to fulfill a legislative mandate directing the agency to review condom labeling to ensure information on the products' ability to prevent human papillomavirus (HPV) is "medically accurate." HPV recently was added to federal lists of known cancer-causing agents because certain strains are linked to cervical cancer. Last year, FDA pledged to address HPV and condom labeling by year-end as part of a guidance, but the document has yet to be published, Souder and Davis note in a Feb. 11 letter. The reps request FDA provide within 30 days "a date certain as to when the [agency] will finally be in compliance with Public Law 106-554" and "an explanation for the continued delay by FDA in complying with this four-year-old law." Souder spearheaded a similar effort early last year (1"The Tan Sheet" Jan. 5, 2004, In Brief)...
Condom HIV Protection Supported By Panel, Other STDs Inconclusive
Latex condom use lowers the risk of acquiring HIV and gonorrhea, but study data on condoms' effectiveness at reducing the risk of other sexually transmitted diseases is inconclusive, according to a recent National Institutes of Health report.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”